Dr. John Cush RheumNow
2 years ago
Stop Counting Bugs (10.4.2024)
This week’s rants include the microbiome, PsA treatment choices and fishing for P-values in research.
https://t.co/KRoMltgPeM https://t.co/9uAbqV8PDK
Dr. John Cush RheumNow
2 years ago
Genomic profiling of 34 ANCA-assoc vasculitis pts w/ glomerulonephritis suggests activity by cytokine-producing CD4+ & CD8+ T cells & potential for ustekinumab. 4 relapsing GN pts Rx w/ UST & CTX +steroids, w/ good responses, improved GFR and BVAS scores… https://t.co/ospA8CJ6JE https://t.co/HbRpXMec0f
Many have suggested that microbiome and mucosal disruptions are contributors to autoimmunity, especially rheumatoid arthritis (RA). This is partly represented in what is known as the "mucosal hypothesis" to RA. A current review article by Hollers, et al. addresses how distinct mucosal endotypes can serve as drivers or initiators of RA.
Dr. John Cush RheumNow
2 years ago
Postop periprosthetic femoral Fx (POPFF) post hip replacement (THR) is uncommon. POPFF needing surgery 0.92 per 1,000 prostheses years; higher in elderly (1.31) & w/ THR for hip Fx (2.19). 1% risk of POPFF w/in 10yrs of THR (15% these die w/in 1 yr) https://t.co/8u3WUWhHnU https://t.co/LfOSPpYbzw
A UK cross-sectional EHR clinical practice analysis between 2004 and 2020 shows that analgesic prescribing in inflammatory arthritis (IA) patients has declined, but still remains substantial, including opioid prescribing.
Dr. John Cush RheumNow
2 years ago
Korean Claims analysis of 413 radiographic axial spondyloarthritis (TNFi exposed=75 ). Recurrent CV events = 32 per 1,000 person-years; but lower if TNFi Rx'd = 19/1000PYs. TNFi exposure significantly lowered risk of recurrent CV events https://t.co/f69SHpXZCx https://t.co/ofpg0JbrR1
Dr. John Cush RheumNow
2 years ago
Medscapes Diagnostic evaluation of inflammatory myositis patients
Labs
Imaging
EMG/NCV
Muscle Bx
https://t.co/jDNlqypoq8 https://t.co/dBgMgex4Cw
Dr. John Cush RheumNow
2 years ago
2023 EULAR Recommendations on Management of Fatigue
A 2023 EULAR task force has made recommendations to the approach and management of fatigue in patients with inflammatory rheumatic and musculoskeletal diseases (I-RMDs).
https://t.co/0wMEa9IHcH https://t.co/I8OgefJKfy
Dr. John Cush RheumNow
2 years ago
Korean population study shows RA was linked to a higher migraine risk, regardless of seropositivity. Comparison of 42,644 RA vs 213,370 controls - found higher risk of migraine (adj HR 1.21; 1.17–1.26). https://t.co/8jlJ4oV95Z https://t.co/r7hsQpt3u7
Dr. John Cush RheumNow
2 years ago
Full read review of Pathogenic autoantibodies in idiopathic inflammatory myopathies: antisynthetase autoAbs, TIF1, MDA5, SRP, HMGCR, TRIM72, cN1A, FHL1, eIF3 autoantibodies and more https://t.co/uzCmauulWZ https://t.co/twhwCB4xof
Dr. John Cush RheumNow
2 years ago
ASAS Imaging Recommendations for Suspected Spondyloarthritis
ASAS (Assessment of Spondyloarthritis International Society) has convened specialized task force to guide imaging request on patients with suspected/known axial spondyloarthritis (axSpA).
https://t.co/snSKDtToHh https://t.co/wpGSHkTwCD
Dr. John Cush RheumNow
2 years ago
JAMA Patient Education Page - Plantar Fasciitis
Plantar Fasciitis accounts for more than 1 million US clinic visits per year. People at risk include obesity, jobs w/ prolonged standing https://t.co/BzAWmdX8gA https://t.co/bNFSSuN8Xv
Dr. John Cush RheumNow
2 years ago
Pneumocystis Jirovecii Pneumonia Complicating Systemic Vasculitis
A retrospecitive analysis of 62 patients with systemic vasculitis complicated by Pneumocystis jirovecii pneumonia (PJP) showed those with MPA had a higher mortality risk, possibly due to a higher prevalence of… https://t.co/yWjWOXtMwR https://t.co/2aD3EIsi7z
Dr. John Cush RheumNow
2 years ago
Upcoming at #ACR2024 -- New updated Lupus Nephritis management Guidelines. Look for it! https://t.co/i5MbtBHhAb https://t.co/udm2YHYlRi
Dr. John Cush RheumNow
2 years ago
FDA has approved Otulfi (ustekinumab-aauz), a ustekinumab biosimilar for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Otulfi ismade by Fresenius Kabi and Formycon https://t.co/p2h9X0C16W https://t.co/YD0uJSEbaq
